Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | PKM | P14618 | 3/20 | 0.40 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4521506 | 0.88 | CA1 (0.54) | HTR6CA1CA2GRM4ALDH1A1 | |
| SCHEMBL14005233 | 0.86 | HTR6 (0.46) | HTR6CA1CA2GRM4ALDH1A1 | |
| SCHEMBL4223924 | 0.85 | HTR6 (0.52) | HTR6CA1CA2GRM4ALDH1A1 | |
| SCHEMBL14005226 | 0.85 | HTR6 (0.52) | HTR6CA1CA2GRM4ALDH1A1 | |
| SCHEMBL18920680 | 0.84 | HTR6 (0.52) | HTR6CA1CA2GRM4ALDH1A1 | |
| SCHEMBL13891891 | 0.82 | HTR6 (0.50) | HTR6CA1CA2GRM4ALDH1A1 | |
| SCHEMBL13891892 | 0.82 | HTR6 (0.50) | HTR6CA1CA2GRM4ALDH1A1 | |
| SCHEMBL27572536 | 0.82 | CA1 (0.45) | HTR6CA1CA2GRM4ALDH1A1 | |
| SCHEMBL21806794 | 0.81 | CA1 (0.54) | HTR6CA1CA2GRM4ALDH1A1 | |
| SCHEMBL13757301 | 0.81 | HTR6 (0.49) | HTR6CA1CA2GRM4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170107513-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | BANK OF AMERICA, N.A. | 2017-04-20 | — | — | US | disclosed |
| US-9566340-B2 | Monomers and oligonucleotides comprising cycloaddition adduct(s) | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-20160101189-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | BANK OF AMERICA, N.A. | 2016-04-14 | — | — | US | disclosed |
| US-9198972-B2 | Monomers and oligonucleotides comprising cycloaddition adduct(s) | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20130053334-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-02-28 | — | — | US | disclosed |
| WO-2009006089-A2 | A2 ADENOSINE RECEPTOR AGONISTS | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-01-08 | — | — | WO | disclosed |
| US-7446186-B2 | Pyrroles substituted by oligonucleotides | BIOMERIEUX (FR) | 2008-11-04 | — | — | US | disclosed |
| US-7446186-B2 | Pyrroles substituted by oligonucleotides | BIOMERIEUX (FR) | 2008-11-04 | — | — | US | disclosed |
| EP-1578759-A1 | PYRROLES SUBSTITUTED BY OLIGONUCLEOTIDES | BIOMERIEUX SA (FR) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004060904-A1 | PYRROLES SUBSTITUTED BY OLIGONUCLEOTIDES | BIOMERIEUX SA (FR) | 2004-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053334-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | DNMT1, FANCI, PCNA | HTR6 4335/4885CA1 3530/4885CA2 3600/4885 |
| US-20170107513-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | FANCI, PCNA, DNMT1 | HTR6 4340/4885CA1 3275/4885CA2 3237/4885 |
| US-20160101189-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | FANCI, PCNA, DNMT1 | HTR6 4340/4885CA1 3275/4885CA2 3237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.